Académique Documents
Professionnel Documents
Culture Documents
n
t
o
m
a
s
d
i
s
p
p
t
i
c
o
s
n
o
i
n
v
.
Abreviaturas:
No inv.= No investigado. SII = Sndrome de Intestino Irritable.
TRU = Test respiratorio de la rea.
ERGE = Enfermedad por Reflujo GastroEsofgico
Grfico 3. Diagnstico
Dispepsia
funcional
Hp negativo
Hp +
Tto. errad
H.p.
Terapia emp.
basada sntoma
ms molesto.
Dolor epigas.
tipo ulceroso
BBP a dosis
completa x
2 - 4 semanas
Llenura/distens.
Tipo dismotilidad
Proquinticos
Sntomas persisten/
Resolucin Sintomas
Sntomas residuales
Grfico 4. Terpia inicial
BBP
Sntomas
controlados
Ensayo de
retiro de la
medicacin
Remisin
Sntomas
recurren
Dispepsia
resistente
Reconsiderar
diagnstico
Antidepresivos
a dosis bajas
etc.
Sntomas
recurren
Remisin
Repetir terapia
exitosa
Repetir terapia
exitosa
Cambio de
medicacin
endoscopa
dosis altas BBP
Ensayo de
retiro de la
medicacin
Sntomas
persisten
Sntomas
persisten
Sntomas
controlados
Proquinticos
0
0
Grfico 5. Manejo a largo plazo
82
Tpicos Selectos en Medicina Interna - GASTROENTEROLOGA
Tabla 2.- Estudios poblacionales a largo trmino del seguimiento de pacientes con
molestias digestivas altas funcionales, mostrando el porcentaje de pacientes que
permanecen con sintomatologa.
BIBLIOGRAFA SELECCIONADA
1. Perea V. Re-definiendo dispepsia. Rev. Gastroenterol.
Per. 1992; 12: 28-34.
2. Talley NJ, Stanghellini V.,Heading RC y col. Functional
gastroduodenal disorders. GUT;1999:45:suppl.2 .37-43.
3. Rhind JA, Watson L. Gallstone dyspepsia. Br Med J.
1968; 6:1(583):32.
4. Thompson WG, Heaton KW. Functional bowel
disorders in apparently healthy people. Gastro-
enterol. 1980;79(2):283-8.
5. Crean GP, Card WI, Beattie AD, Holden RJ, James
WB, Knill-Jones RP, Lucas RW, Spiegelhalter D.
Ulcerlike dyspepsia. Scand J Gastroenterol Suppl.
1982;79:9-15.
6. Lagarde SP, Spiro HM. Non-ulcer dyspepsia. Clin
Gastroenterol. 1984 ;13(2):437-46.
7. Talley NJ, Piper DW. The association between non-
ulcer dyspepsia and other gastrointestinal disorders.
Scand J Gastroenterol. 1985;20(7):896-900.
8. Gustavsson S, Bates S, Adami HO, Loof L, Nyren O.
Dyspepsia. Definition and discussion of nomencla-
ture. Scand J Gastroenterol Suppl. 1985;109:11-3.
9. Talley NJ, Phillips SF. Non-ulcer dyspepsia: potential
causes and pathophysiology. Ann Intern Med. 1988
Jun;108(6):865-79.
10. Colin-Jones DG. The management of dyspepsia.
Scand J Gastroenterol Suppl. 1988;155:96-100
11. Heading RC. Definitions of dyspepsia. Scand J
Gastroenterol Suppl. 1991;182:1-6.
12. Yrriberry S. Dispepsia, conceptos, tipos de dispepsia,
fi si opatol og a, di agnsti co y tratami ento.
Diagnstico.2003:43;209-218.
13. Len-Bara R, Berendson-Seminario R, Biber-Poillevard
M. Reevaluacin clnica, experimental y filosfica de
la dispepsia. Diagnstico 2000;39:266-69.
14. Len-Bara R, Berendson-Seminario R, Biber-Poille-
vard M. Enjuiciamiento de la definicin y clasificacin
actual de la dispepsia. Rev. AIGE 2001;4:22-25.
15. McQuaid KR. Dyspepsia. En Feldman M, Friedman LS
& Sleisenger MH. Sleisenger&Fortrans Gastroin-testinal
and liver disease 2006 Online Elsevier.102- 118.
16. Drossman DA, Richter JE, Talley NJ y col. The
functional gastrointestinal disorders, Boston: Little,
Brown, 1994.
Referencia y diagnstico Perodo Seguimiento Porcentaje de pacientes
siguen con sintomatologa
Weir y Backett
Dispepsia 3 meses 3 aos 65
Jones y Lydeart
Dispepsia 6 meses 2 aos 74
Talley y col.
Dolor abdominal 1 ao 12-20 meses 82
Dispepsia 86
SII (criterios Manning) 86
SII (criterios Roma) 93
Agreus y col.
Reflujo sntoma predom. 3 meses 1 ao 41
Dispepsia 43
SII 50
Libre de sntomas 80
Kay y Jorgensen
Dispepsia 1 ao 5 aos 75
Locke y col.
Dispepsia 1 ao 4 aos 51
SII 25
Agrus y col.
Sntomas predom. reflujo 3 meses 7 aos 29
Dispepsia 30
SII 55
Libre de sntomas 65
SII: Sndrome de Intestino Irritable
83
Dispepsia - Dr. Alberto Zolezzi Francis
17. Agrus L, Svrdsudd K, Nyren O y col. Irritable bowel
sndrome and dispepsia in general population:
overlap and lack of stability over time. Gastroenterol
1995: 109;671-680.
18. Talley NJ y Holtmann G. Approach to the patient
with dyspepsia and related functional gastrointestinal
complaints. In Yamada Yamada T, Alpers DH,
Kaplowitz Neil, Laine L, Owyang C, Powell DW.
Textbook of Gastroenterology Lippincott Williams &
Wilkins, 4th Edition,2003.
19. Barrs P, Pamo O. Molestias digestivas en la pobla-
cin adulta de Lima. Rev Gastroenterol Per 1989;
9:131-138.
20. Curioso WH, Donaires N, Basilio C, Ganoza C, Len
Bara R. Prevalencia y asociacin de la dispepsia y el
sndrome de intestino irritable en una comunidad
de la selva peruana. Rev Gastroenterol Per 2002;
22: 129-140.
21. Agrus L. Natural history of dispepsia. Gut 2002;
50(suppl IV):iv2-iv9.
22. Thumshirn M. Pathophysiology of functional
dispepsia. Gut.2002;51,Suppl1:63-66.
23. Holtmann G, Talley NJ. Clinicals Manual on mana-
ging dyspepsia. LSC. 2000
24. Graydanus MP, Vassallo M, Camilleri M el al. Neurohu-
moral factors in functional dyspepsia: Insights on
pathophysiological mechanisms. Gastroenterol 1991;
100:1311-1318.
25. Troncon LE, Bennett RJ, Ahluwalia NK et al. Abnormal
intragastric distribution of food during gastric
emptying in functional dyspepsia patients. Gut
1994;35:327-32.
26. Tack J, Piessevaux H, Coulie B et al. Role of a impaired
gastric accommodation to a meal in non-ulcer ulcer
dyspepsia. Gastroenterol 1998;115:1346-52.
27. Stanghellini V, Ghidini C, Maccarini MR et al. Fasting
and postprandial gastrointestinal motility in ulcer and
nonulcer dyspepsia. Gut 1992; 33: 184-90.
28. Thumshirn M, Camilleri M, Saslow SB et al. Gastric
accommodation in non ulcer dyspepsia and the roles
of Helicobacter pylori and vagal function. Gut 1999;
44:55-64.
29. Laine L, Schonfeld P, Fennerty MB. Therapy for
Helicobacter pylori in patients with nonulcer
dyspepsia. Ann Intern Med 2001; 134: 361-9.
30. Rabeneck L, Wray N, Graham D: Managi ng
dyspepsia: What do we know and what do we need
to know? Am J Gastroenterol 1998;93:920.
31. Peterson W, Cryer B: COX-1 sparing NSAIDs-is the
enthusiasm justified? JAMA 1999;282:1961.
32. Brun J, Jones J: Nonsteroidal anti-inflammatory drug-
associated dyspepsia: The scale of the problem. Am
J Med 2001;110:12S.
33. Stanghellini V, Tosetti C, Barbara G, et al: The conti-
nuing dilemma of dyspepsia. Aliment Pharmacol Ther
2000;14:23.
34. Talley N, Silverstein M, Agreus L, et al: AGA technical
review: Evaluation of dyspepsia. Gastroenterol
1998;114:582.
35. Frank L, Kleinman L, Ganoczy D, et al: Upper
gastrointestinal symptoms in North America:
Prevalence and relationship to health care utilization
and quality of life. Dig Dis Sci 2000;45:809.
36. Stanghellini V: Three-month prevalence rates of
gastrointestinal symptoms and the influence of
demographic factors: Results from the Domestic
International Gastroenterology Surveillance Study
(DIGEST). Scand J Gastroenterol 1999;34:20.
37. Talley N, Weaver A, Tesmer D, et al: Lack of
discriminant value of dyspepsia subgroups in patients
referred for endoscopy. Gastroenterol
1993;105:1378.
38. Wayman J, Griffin S, Campbell F: Is functional
dyspepsia largely explained by gastro-oesophageal
refl ux di sease? Bai l l i eres Cl i n Gastroenterol
1998;12:463.
39. Rabeneck L, Wray N, Graham D: Managi ng
dyspepsia: What do we know and what do we need
to know? Am J Gastroenterol 1998; 93:920.
40. Clouse RE. Approach to the patient with dyspepsia
in: Wolfe MM (ed) Therapy of digestive disorders.
WB Saunders Co. 2000.
41. Delaney, BC; Moayyedi, P; Forman, D. Initial mana-
gement strategies for dispepsia , The Cochrane Database
of Systematic Reviews, 2005; Vol (3), [no page #]
42. Wiseman LR, Faulds D. Cisapride. An updated review
of its pharmacology and therapeutic efficacy as a
prokinetic agent in gastrointestinal motility disorders.
Drugs 1994;47: 116-152.
43. Otaka M, Jin M, Odashima M, Matsuhashi T, Wada
I, Horikawa Y, Komatsu K, Ohba R, Oyake J,
Hatakeyama N, Watanabe S. New strategy of therapy
for functional dyspepsia using famotidine, mosapride
and amitriptyline. Aliment Pharmacol Ther. 2005
Jun;21 Suppl 2:42-6.
44. Cho YK, Choi MG, Kim SH, Lee IS, Kim SW, Chung
IS, Lee SY, Choi SC, Seol SY. The effect of mosapride
on quality of life in functional dyspepsia : Korean J
Gastroenterol. 2004 Mar;43(3):160-7.
45. Hallerback BI, Bommelaer G, Bredberg E, Campbell
M, Hellblom M, Lauritsen K, Wienbeck M, Holmgren
LL. Dose finding study of mosapride in functional
dyspepsia: a placebo-controlled, randomized study.
Aliment Pharmacol Ther. 2002 May;16(5):959-67.
46. Prakash C, Lustman PJ, Freedland KE et al. Triciclic
antidepressants for functional nausea and vomiting:
clinical outcoming in 37 patients. Dig Dis Sci
1998;43:1951-6.
47. Talley N, Vakil N. Guidelines for the management of
dyspepsia. Am J Gastroenterol 2005;100:2324-37.